BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19843880)

  • 1. Palliative oncology: thalidomide.
    Prommer EE
    Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects of thalidomide administration in patients with neoplastic diseases.
    Dimopoulos MA; Eleutherakis-Papaiakovou V
    Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide: dual benefits in palliative medicine and oncology.
    Davis MP; Dickerson ED
    Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The revival of thalidomide: an old drug with new indications].
    Laffitte E
    Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide for the treatment of multiple myeloma.
    Hattori Y; Iguchi T
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
    Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
    Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thalidomide--new prospective therapy in oncology].
    Pałgan K; Pałgan I
    Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potential side effects of thalidomide].
    Rev Prat; 2006 Jan; 56(1):52. PubMed ID: 16548249
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
    Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
    Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide: mechanisms of action.
    Paravar T; Lee DJ
    Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thalidomide in oncological and hematological diseases].
    Kivivuori SM; Anttila P
    Duodecim; 2010; 126(12):1413-9. PubMed ID: 20617746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
    Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G
    Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide: current and potential clinical applications.
    Calabrese L; Fleischer AB
    Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    Lokhorst HM; Schmidt-Wolf I; Sonneveld P; van der Holt B; Martin H; Barge R; Bertsch U; Schlenzka J; Bos GM; Croockewit S; Zweegman S; Breitkreutz I; Joosten P; Scheid C; van Marwijk-Kooy M; Salwender HJ; van Oers MH; Schaafsma R; Naumann R; Sinnige H; Blau I; Delforge M; de Weerdt O; Wijermans P; Wittebol S; Duersen U; Vellenga E; Goldschmidt H; ;
    Haematologica; 2008 Jan; 93(1):124-7. PubMed ID: 18166796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.